10-Q: Tyra Biosciences Advances Clinical Pipeline

Tyra Biosciences reports increased R&D spend and net loss in Q2 2025, while maintaining a strong cash position to fund operations through at least 2027.

Summary

• Tyra Biosciences, a clinical-stage biotechnology company, reported a net loss of $56.2 million for the six months ended June 30, 2025, an increase from $36.9 million for the same period in 2024.
• Research and development expenses significantly increased to $49.3 million for the six months ended June 30, 2025, up from $35.2 million in the prior year, primarily due to clinical trial activities for BEACH301, SURF302, and SURF431.
• General and administrative expenses also rose to $14.0 million for the six months ended June 30, 2025, compared to $10.7 million in 2024, driven by headcount growth and associated personnel costs.
• The company held $296.3 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Management believes current cash resources are sufficient to fund operating expenses and capital expenditures through at least 2027.
• Key clinical milestones achieved include dosing the first patient in the SURF302 study for non-muscle invasive bladder cancer in June 2025 and commencing patient dosing for TYRA-430 in hepatocellular carcinoma in April 2025.
• The company expects to dose the first child in the BEACH301 study for pediatric achondroplasia in the third quarter of 2025 and report initial three-month CR data for SURF302 in the first half of 2026.
• Tyra Biosciences terminated its 2022 ATM Sales Agreement and entered into a new 2025 ATM Sales Agreement with TD Securities (USA) LLC for up to $150.0 million, with no shares sold under the new agreement as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company is executing its clinical development plan with multiple programs advancing, supported by a solid cash runway through at least 2027. While net losses are increasing, this is expected for a clinical-stage biotech. The promising early clinical data for dabogratinib is a positive signal. The new ATM facility provides flexibility for future capital needs.

Positives

• Strong cash, cash equivalents, and marketable securities balance of $296.3 million as of June 30, 2025.
• Sufficient cash runway projected to fund operations through at least 2027, providing financial stability for ongoing development.
• Advancement of multiple clinical programs: first patient dosed in SURF302 (NMIBC) and TYRA-430 (HCC) in Q2 2025.
• Anticipated dosing of the first child in the BEACH301 study (pediatric achondroplasia) in Q3 2025, indicating progress in a significant program.
• Interim data from SURF301 (mUC) showed a 54.5% confirmed partial response rate in FGFR3+ patients (6 out of 11) at doses equal to or greater than 90 mg once daily, suggesting promising efficacy.

Negatives

• Net loss increased significantly to $56.2 million for the six months ended June 30, 2025, compared to $36.9 million in the prior year.
• Research and development expenses increased by $14.1 million for the six months ended June 30, 2025, reflecting higher costs associated with clinical trial activities.
• General and administrative expenses increased by $3.3 million for the six months ended June 30, 2025, primarily due to headcount growth.
• Interest and other income decreased by $1.9 million for the six months ended June 30, 2025, due to lower interest rates and reduced cash balances.
• Cash used in operating activities increased to $49.1 million for the six months ended June 30, 2025, indicating a higher cash burn rate.

Risks

• The company has incurred significant operating losses since inception and expects to continue incurring substantial and increasing losses for the foreseeable future.
• Uncertainty regarding the successful development, regulatory approval, and commercialization of product candidates, which may never occur.
• Future capital requirements are substantial and depend on numerous factors, including the scope and results of preclinical studies and clinical trials, manufacturing costs, and regulatory review.
• Inability to raise additional funds or enter into collaborations on favorable terms, or at all, which could force delays, limitations, or termination of development programs.
• Potential for dilution of stockholder ownership interest if additional capital is raised through equity or convertible debt securities.
• Agreements related to debt or equity financing may include covenants restricting the company's ability to take specific actions.
• Relinquishing valuable rights to technologies, future revenue streams, or product candidates if funds are raised through collaborations.
• Delays or issues in development, manufacturing, or regulatory processes, potentially exacerbated by geopolitical instability, inflation, interest rates, tariffs, trade policies, or pandemics.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses as it advances product candidates through preclinical studies and clinical trials, expands its pipeline, and incurs costs associated with being a public company. It anticipates financing future cash needs through equity offerings, debt financings, or collaborations, as it does not expect to generate revenue from product sales for several years, if ever. The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations through at least 2027.

Management Comments

• We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, with an initial focus on Fibroblast Growth Factor Receptor (FGFR) biology.
• Our in-house precision medicine platform, SNP, enables rapid and precise drug design through iterative molecular SNPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.
• We expect to dose the first child in the BEACH301 study in the third quarter of 2025.
• We dosed the first patient in the SURF302 study in June 2025. We expect to report initial three-month CR data in the first half of 2026.
• Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of June 30, 2025 will be sufficient to fund our operating expenses and capital expenditures through at least 2027.

Industry Context

Tyra Biosciences operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically targeting oncology and genetically defined conditions through Fibroblast Growth Factor Receptor (FGFR) biology. The company's SNP platform aims to differentiate its drug design by predicting potency, selectivity, and tolerability, addressing common challenges with first-generation inhibitors. Its focus on precision medicines aligns with a broader industry trend towards targeted therapies for specific genetic alterations, which can offer improved efficacy and reduced off-target toxicities compared to traditional treatments. The significant R&D investment and ongoing clinical trials reflect the typical progression for a company at this stage, aiming to bring novel small molecules to market in areas with high unmet medical needs like bladder cancer, achondroplasia, hepatocellular carcinoma, and cholangiocarcinoma.

Comparison to Industry Standards

• The company's reported 54.5% confirmed partial response rate for dabogratinib in FGFR3+ metastatic urothelial carcinoma (mUC) patients (6 out of 11) at doses equal to or greater than 90 mg once daily is a promising early signal. For context, other FGFR inhibitors in mUC have shown varying response rates; for example, Erdafitinib (Balversa), an approved pan-FGFR inhibitor, demonstrated a 40% objective response rate in patients with susceptible FGFR3 alterations in its pivotal trial (BLC2001). While Tyra's data is preliminary and from a smaller cohort, it suggests competitive activity.
• The company's cash runway through at least 2027 is a positive indicator of financial stability for a clinical-stage biotech, especially given the high burn rates typical in drug development. This provides a longer operational window compared to some peers who might have shorter cash runways, reducing immediate financing pressure.
• The increase in R&D expenses from $35.2 million to $49.3 million for the six months ended June 30, 2025, is consistent with industry trends for clinical-stage companies advancing multiple programs into later phases or initiating new trials. This reflects the escalating costs associated with patient enrollment, site payments, and manufacturing for clinical supply, which is a standard progression in the biotech sector.

Corporate Governance

Legal Proceedings

• Not subject to any material legal proceedings as of June 30, 2025, and no material legal proceedings are currently pending or threatened.

Related Party Transactions

• In February 2024, the company completed a private placement where related parties, Boxer Capital and RA Capital, purchased 4,780,846 shares of common stock and pre-funded warrants to purchase 2,243,737 shares of common stock, resulting in aggregate gross proceeds of approximately $91.4 million.
• In October 2024, the company entered into an exchange agreement with Boxer Capital and RA Capital, where they exchanged common stock for pre-funded warrants to acquire an aggregate of 3,000,000 shares of common stock (2,000,000 for Boxer Capital, 1,000,000 for RA Capital), with no cash exchanged.
• During the six months ended June 30, 2025, Boxer Capital exercised 2,000,000 of the Exchange Warrants and 237 of the 2024 Pre-Funded Warrants in cashless transactions, resulting in 2,000,069 shares of common stock being issued.

Stakeholder Impact

• **Shareholders**: Experience increased net losses and R&D expenses, which are typical for a clinical-stage biotech. Potential for future dilution due to anticipated capital raises. However, the extended cash runway and clinical progress provide stability and potential for long-term value creation if trials succeed.
• **Employees**: Headcount growth is noted, leading to increased personnel expenses and stock-based compensation, indicating continued investment in human capital. The equity incentive plans and employee stock purchase plan offer opportunities for employee participation in company success.
• **Customers (Future Patients)**: Advancement of multiple drug candidates (dabogratinib, TYRA-430, TYRA-200) in oncology and genetically defined conditions offers potential new treatment options for diseases like bladder cancer, achondroplasia, hepatocellular carcinoma, and cholangiocarcinoma.
• **Creditors/Suppliers**: The company's strong cash position and projected runway through at least 2027 indicate a healthy ability to meet short-term and medium-term financial obligations to suppliers and other creditors.
• **Regulatory Authorities**: Ongoing clinical trials and future regulatory filings will require continued engagement and compliance with bodies like the FDA and other non-U.S. regulators.

Next Steps

• Dose the first child in the BEACH301 study (pediatric achondroplasia) in the third quarter of 2025.
• Report initial three-month complete response (CR) data for the SURF302 study (NMIBC) in the first half of 2026.
• Continue dose optimization for dabogratinib in the SURF301 study (mUC) in preparation for potential future Phase 2 studies.
• Continue evaluation of TYRA-430 in the global Phase 1 SURF431 study for advanced HCC and other solid tumors.
• Continue evaluation of TYRA-200 in the multicenter, open-label Phase 1 SURF201 study, focusing on proof-of-concept in FGFR2-driven ICC resistant to previous inhibitors.
• Potentially raise additional capital through equity offerings, debt financings, or collaborations as needed to fund operations beyond 2027.

Key Dates

Recommendation

Tyra Biosciences is a clinical-stage biotechnology company with a high-risk, high-reward profile typical of the sector. While the company continues to incur significant losses and burn cash, this is expected as it advances multiple promising drug candidates through costly clinical trials. The reported cash runway through at least 2027 provides a crucial buffer, mitigating immediate liquidity concerns. The early clinical data for dabogratinib in mUC is encouraging, and the initiation of new trials for other programs demonstrates pipeline progression. However, the success of these programs is uncertain, and future capital raises will likely be necessary, potentially leading to dilution. Given the current stage of development, the stock is a 'hold' for investors comfortable with biotech volatility, awaiting further significant clinical data readouts that would de-risk the pipeline and potentially justify a 'buy' recommendation.

Keywords

Biotechnology, Clinical-stage, Oncology, Precision Medicine, FGFR, Dabogratinib, TYRA-300, TYRA-430, TYRA-200, Bladder Cancer, Achondroplasia, Hepatocellular Carcinoma, Cholangiocarcinoma, Drug Development, SEC Filing, 10-Q